US 12,084,431 B2
Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
Landon J. Durak, Cambridge, MA (US); Marianne Langston, Cambridge, MA (US); Pradeep Kumar Sharma, Cambridge, MA (US); Thai Hiep Nguyen, Dorchester, MA (US); Shuanglian Li, Cambridge, MA (US); and Xiaoguang Zhang, Cambridge, MA (US)
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED, (JP)
Appl. No. 17/055,164
Filed by ARIAD Pharmaceuticals, Inc., Cambridge, MA (US)
PCT Filed May 13, 2019, PCT No. PCT/US2019/032002
§ 371(c)(1), (2) Date Nov. 13, 2020,
PCT Pub. No. WO2019/222093, PCT Pub. Date Nov. 21, 2019.
Claims priority of provisional application 62/671,166, filed on May 14, 2018.
Claims priority of provisional application 62/671,182, filed on May 14, 2018.
Prior Publication US 2021/0309640 A1, Oct. 7, 2021
Int. Cl. C07D 403/04 (2006.01); A61P 35/00 (2006.01)
CPC C07D 403/04 (2013.01) [A61P 35/00 (2018.01); C07B 2200/13 (2013.01)] 30 Claims
 
1. A succinate salt of Compound (A) in a crystalline form

OG Complex Work Unit Chemistry
wherein the crystalline form comprises an X-ray powder diffraction pattern expressed, in terms of 2-theta, at 8.3±0.20, 9.9±0.20, 11.7±0.20, and 22.5±0.20 degrees.